Express Healthcare
Home  »  Tata Elxsi awarded global services deal from Aesculap AG for medical device engineering

Tata Elxsi awarded global services deal from Aesculap AG for medical device engineering

0 125
Read Article

Opens a dedicated Global Engineering Center for Aesculap as part of the strategic multi-year engagement

Tata Elxsi, a global design and technology services company, announced the opening of a Global Engineering Center (GEC) with Aesculap AG, a subsidiary of B. Braun, one of the world´s leading manufacturers of medical devices and pharmaceutical products and services.

Tata Elxsi has been selected as the global engineering services partner by Aesculap. The GEC is part of a strategic multi-year engagement in the field of engineering services.

The GEC serves as a platform of talent and expertise for product design & engineering, regulatory support and clinical evaluation services. This center will be essential to accelerate innovation, drive the transformation and growth for Aesculap‘s medical business.

Commenting on the deal, Martin Schaeuble, Vice President Abdominal and Cardio-Thoracic Surgery, Aesculap said,” Tata Elxsi has proven to be the right partner, bringing the right mix of technical expertise and programme management skills. Together with Tata Elxsi we are in the position to continue our innovation activities as well as adherence across Aesculap‘s product portfolio.”

 “We are elated to be selected as a strategic partner of Aesculap. It is an absolute honour for us to be part of this journey in supporting Aesculap through our Global Engineering Center, bringing together integrated competencies in R&D and innovation, digital technologies, deep domain understanding of medical devices and ever-evolving regulatory standards. This further consolidates our position in the Medical Devices and Healthcare market in Europe, and strengthens our relationship with Aesculap and the B. Braun group,” said Nitin Pai, Chief Strategy Officer and CMO, Tata Elxsi.

Leave A Reply

Your email address will not be published.